Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

BENEFITS HUMAN EPIDYDIMIS PROTEIN (HE4) COMPARED TO TRADITIONAL USED TUMOR MARKERS IN GYNECOLOGICAL ONCOLOGY (CROSBI ID 260055)

Prilog u časopisu | pregledni rad (stručni) | domaća recenzija

Špacir Prskalo, Zvjezdana ; Gaće, Mihaela ; Dobrijević, Sanja ; Mayer, Ljiljana BENEFITS HUMAN EPIDYDIMIS PROTEIN (HE4) COMPARED TO TRADITIONAL USED TUMOR MARKERS IN GYNECOLOGICAL ONCOLOGY // Libri oncologici : Croatian journal of oncology, 43 (2015), 1-3; 9-14

Podaci o odgovornosti

Špacir Prskalo, Zvjezdana ; Gaće, Mihaela ; Dobrijević, Sanja ; Mayer, Ljiljana

engleski

BENEFITS HUMAN EPIDYDIMIS PROTEIN (HE4) COMPARED TO TRADITIONAL USED TUMOR MARKERS IN GYNECOLOGICAL ONCOLOGY

Ovarian cancer is, with its high incidence and mortality, a worldwide problem. One reason for this is the lack of symptoms. The second reason is practically non-existant screening for ovarian cancer. Until recently, the only routinely used marker for ovarian abnormalities was CA125. Determination of HE4 levels, together with those of CA125 and the calculation of the ROMA index, is a suitable method for improving primary detection of ovarian cancer. The measurement of serum HE4 is a useful method for diff erential diagnosis between benign gynecologic disease and ovarian cancer

ovarian cancer, CA125, HE4 (Human epidydimis protein), ROMA (Risk of Ovarian Malignancy Algorithm) index

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

43 (1-3)

2015.

9-14

objavljeno

0300-8142

2584-3826

Povezanost rada

Javno zdravstvo i zdravstvena zaštita, Kliničke medicinske znanosti, Temeljne medicinske znanosti

Indeksiranost